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Abstract
First-episode psychosis (FEP) is a psychiatric disorder, characterised by positive and negative symptoms, usually
emerging during adolescence and early adulthood. FEP represents an early intervention opportunity for intervention
in psychosis. Redox disturbance and subsequent oxidative stress have been linked to the pathophysiology of FEP.
Exercise training can perturb oxidative stress and rebalance the antioxidant system and thus represents an intervention
with the potential to interact with a mechanism of disease. The aim of this study was to assess the effect of exercise on
markers of redox status in FEP. Twenty-two young men were recruited from Birmingham Early Intervention services
and randomised to either a 12-week exercise programme or treatment as usual (control). Measures of blood and brain
glutathione (GSH), markers of oxidative damage, inflammation, neuronal health, symptomology and habitual physical
activity were assessed. Exercise training was protective against changes related to continued psychosis.
Symptomatically, those in the exercise group showed reductions in positive and general psychopathology, and stable
negative symptoms (compared to increased negative symptoms in the control group). Peripheral GSH was increased
by 5.6% in the exercise group, compared to a significant decrease (24.4%) (p= 0.04) in the control group. Exercise
attenuated negative changes in markers of neuronal function (brain-derived neurotrophic factor), lipid damage
(thiobarbituric acid-reactive substances) and total antioxidant capacity. C-reactive protein and tumour necrosis factor-α
also decreased in the exercise group, although protein and DNA oxidation were unchanged. Moderate-intensity
exercise training has the ability to elicit changes in markers of oxidative stress and antioxidant concentration, with
subsequent improvements in symptoms of psychosis.
Introduction
First-episode psychosis (FEP) is a psychiatric disorder,
characterised by positive and negative symptoms, usually
emerging during adolescence and early adulthood1. It is
well described that a delay in FEP treatment can lead to
cognitive alterations and worsened functional outcome2.
FEP patients are highly heterogeneous in symptom pro-
file, treatment response and cannabis consumption, and
there is a need for improved characterisation of bio-
markers related to disease pathophysiology in order to
better understand pathology of disease. Many of the
biochemical perturbations observed in this population are
associated with the psychosis phenotype and thus repre-
sent targets for treatment.
Several aspects of (neuro) physiology are altered in FEP
and schizophrenia patients, including dysfunctional neu-
rotransmitter systems3,4, decreased synaptic plasticity5
and reduced hippocampal volume6. In addition, inflam-
mation and cellular redox status is also altered. This
is often termed oxidative stress, and represents an
imbalance between reactive radicals or oxidants, which
are naturally produced in aerobic metabolism, and
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antioxidants, which balance and quench oxidants to allow
essential signalling processes, but prevent damage to
biomolecules leading to cell injury or death7. Brain-
derived neurotrophic factor (BDNF), which has an
essential role in neural signal transmission and synaptic
plasticity, is depleted in FEP8. It has also been suggested
that BDNF is responsible for protecting against oxidative
stress by upregulating the expression of antioxidant
enzymes9, highlighting the value of BDNF as a candidate
biomarker of psychosis.
Glutathione (GSH) is the most abundant antioxidant
that acts as a scavenger of reactive oxygen species, with a
primary role of maintaining the intracellular redox bal-
ance10. GSH has been implicated in the pathogenesis of a
range of neurodegenerative and psychotic diseases11. FEP
patients have shown as much as a 52% reduction in GSH
compared with controls12,13. Indeed, evidence of per-
turbed redox homeostasis in FEP and schizophrenia is
plentiful. There have been reports of reduced total
GSH13–15, increased oxidised GSH (GSSG)15, increased
lipid16,17, protein18,19 and DNA damage20,21. However,
conflicting data by Reddy et al.22 also showed no
impairment of antioxidant defences in comparison with a
healthy control group, hypothesising that disease stage is
related to progression of oxidative stress accumulation. A
study by Fraguas et al.14 assessed the relationship between
grey matter volume and GSH in the brains of schizo-
phrenia patients. The study highlighted a progressive
blood GSH decline over the 2-year follow-up period, as
well as a relationship between grey matter loss and
blood GSH.
The brain is a particularly vulnerable target for free-
radical-mediated damage due to a high level of oxygen
consumption23,24, and high lipid content19. When this
high oxygen concentration is coupled with a modest
endogenous antioxidant concentration25, and inability of
GSH to cross the blood–brain barrier (BBB), particularly
from exogenous supplementation or circulating pools, the
antioxidant defence system is stretched. Assessment of
brain redox state in vivo is not easy, and peripheral
markers are usually employed as an estimate of whole-
body oxidative environment and antioxidant concentra-
tion. However, recent methodological advances in mag-
netic resonance spectroscopy (MRS) have allowed the
quantification of GSH in the cerebral tissue26.
Exercise has been identified as an adjunctive treatment
for psychosis as it has the ability to improve clinical
symptoms27 and has the potential to restore redox
homeostasis, as demonstrated in healthy populations28.
However, no study has proven the efficacy of exercise in
altering the underlying pathology of disease. Studies
employing moderate-intensity aerobic exercise29 and
combined aerobic and resistance training30 across 16 and
12 weeks, respectively, have resulted in reduced psychotic
symptoms assessed by the Positive and Negative Symp-
tom Scale (PANSS). Acil et al.31 described a 14% increase
in quality of life, as well as a decrease of positive and
negative symptoms that define the schizophrenic
phenotype.
Mechanisms underpinning exercise adaptation are well
established in studies of healthy participants and are
characterised by an antioxidant response to radical sig-
nals32. Elokda and Nielsen33 demonstrated adaptations to
either aerobic training or combined aerobic and circuit
weight training (standardised workload). Both training
programmes led to a significant increase in GSH, and
reduced oxidised GSH (GSSG). Additionally, exercise
training has the potential to modify other indices of redox
status. Studies in health volunteers have shown that
exercise training may elevate BDNF34 and reduce oxida-
tive damage markers, including malondialdehyde (lipid
peroxidation) and protein carbonyl concentration35.
Furthermore, exercise training is beneficial in reducing
circulating proinflammatory cytokines36. There is robust
evidence to implicate a systemic proinflammatory state in
FEP. Inflammation and oxidative stress are strongly linked
in a number of pathologies. Systematic review37 confirms
elevated proinflammatory cytokines in drug-naive FEP,
including interleukin-6 (IL-6), tumour necrosis factor-
alpha (TNF-α), IL-1β and sIL-2R, and there is clear evi-
dence of elevated IL-6 in childhood, predicting risk for
both psychosis and metabolic dysfunction. Regular phy-
sical activity can lead to reductions in circulating IL-638,39,
TNF-α40 and C-reactive protein (CRP)41,42.
The aim of this exploratory pilot study was to assess the
effect of 12 weeks of exercise training on the GSH system
in FEP, via in vivo brain and peripheral blood measures.
To add context around changes in GSH, measures of
oxidative damage, inflammation and neuronal health were
assessed, as well as symptoms of psychosis.
Methods
Participants
Male patients, aged 16–35 years, with a diagnosis of FEP
(as identified by a psychiatrist in keeping with ICD-10 F
20-29, F31.2, 32.3 diagnostic criteria), were recruited from
the community-based Birmingham Early Intervention
service. Patients were within 3 years of first presentation
of illness. Male patients only were recruited, since the
oestrogen cycle has a significant effect on antioxidant
concentration, in particular GSH43. Eligibility criteria
were assessed initially by the primary care coordinators
for each patient, followed by assessment of habitual
activity to ensure a sedentary lifestyle, as well as the use of
a general health questionnaire to assess cannabis use and
confirm the patient was free from medical conditions that
prevent participation in moderate-intensity aerobic exer-
cise. A sample size of 28 was calculated, using the
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G*Power software44, based on intervention-associated
change in GSH. Exclusion criteria included failure to
adhere to pretesting requirements, for example, provide a
blood sample, or significant risk to self of others as
identified by the clinical team. Study assessments took
place at baseline, mid-point (for the exercise group only)
and post intervention. This study was commenced fol-
lowing approval from the NIHR HRA ethics committee
(West Midlands- Edgbaston REC 17/WM/0412). Inter-
vention design, quality and patient-oriented outcomes
were assessed and are summarised by Fisher et al.45.
Randomisation
Following consent, participants were randomised to either
the exercise intervention group or the control arm (treat-
ment as usual) of the study. A block randomisation method
(http://www.randomization.com)46,47 was used to allow for
equal group distribution in the event of poor recruitment.
Exercise intervention
Exercise sessions were designed and supervised by a
trained researcher at the School of Sport, Exercise and
Rehabilitation Sciences, University of Birmingham. The
intervention was 12 weeks long, with each participant
required to exercise at least 2 times per week, for
40–60 min per session. In an effort to maximise atten-
dance and compliance, which has historically been diffi-
cult in this group48, participants were given a choice of
different activities to undertake at each session (available
exercise: running; cycling; swimming; tennis; squash;
badminton; circuit training and football). Each training
session was standardised by heart rate target zone, based
on 70–80% HRmax (maximum heart rate). The minimum
training intensity for improvement in aerobic fitness is
55–65% HRmax49; therefore, in order to observe a
meaningful and significant effect of exercise, intensity was
set above this. The ACSM (American College of Sports
Medicine) recommends 50% VO2max (maximum rate of
oxygen consumption) as a minimum intensity for exercise
training50, which corresponds to 65% HRmax. The rela-
tionship between HR and VO2 reflect energy expenditure
in a linear fashion, up to 85% HRmax51. Energy con-
sumption, resting heart rate, active calories and intensity
minutes (equivalent to moderate-intensity exercise) was
tracked at three time-points in the intervention period
(baseline, mid-intervention and post intervention), and for
the duration of each exercise bout by Garmin VivoSmart™
HR activity monitor (Garmin, USA).
Blood sampling
Cephalic/cubital venous blood samples were taken at
pre-intervention (0 weeks), mid-intervention (6 weeks)
and post-intervention (13 weeks) time-points, into BD
Vacutainer® MAP K2EDTA 1.0 mg tubes (BD, USA).
Following removal of whole blood (2 × 1mL) for comet
assay and GSH analysis, samples were centrifuged (2000 r.
p.m., 15 min, 10 °C) and the resultant plasma was ali-
quoted for subsequent determination of FRAP (ferric-
reducing ability of plasma), TBARS (thiobarbituric acid-
reactive substances), 8-isoprostane, BDNF, IL-6, CRP,
TNF-α and protein carbonyl. All samples were stored at
−80 °C for a maximum of 9 months until analysis.
MRS GSH measurement
Scans were conducted at the Birmingham University
Imaging Centre, using a 3 Tesla Phillips Achieva MRI
(magnetic resonance imaging) scanner, with a 32-channel
head coil. The 1H single-voxel Mescher–Garwood point-
resolved spectroscopy method of acquisition was employed,
with repetition time= 2 s; echo time= 131ms; 55Hz
bandwidth editing pulse at 4.56 p.p.m.; and 1024 complex
data points acquired at a sampling frequency of 2000Hz,
followed by water suppression. The MRS protocol included
a T1-weighted structural MRI for MRS planning (5min).
The volume of interest was located in the anterior cingulate
cortex (30 × 30 × 20mm3) (Fig. 1). Total MRS scan time for
GSH measurement was 18min. Spectral alignment was
completed using the RATS (Robust Alignment to a Target
Spectrum) method52, implemented in R (v3.5.0) (Vienna,
Austria), and integrated into the SPANT (SPectroscopy
ANalysis Tools) package (v0.12.0) for MRS analysis. GSH
was then fitted using TARQUIN. An example spectrum is
detailed in Fig. 1, following post-processing, with the GSH
peak highlighted.
Blood GSH
Whole-blood GSH concentration was determined
using a commercially available luminescence-based assay
(GSH-Glo™ Glutathione Assay, Promega, WI, USA). The
assay was undertaken according to the manufacturer’s
instructions.
Comet assay
Cells were prepared for assessment of single-strand
DNA strand breaks, characterised by Singh et al.53.
Thawed whole-blood samples were used for analysis,
breaking away from the conventional use of isolated
mononuclear cells, replicating the protocol described by
Akor-Dewu et al.54. Active SYBR-GOLD nucleic acid gel
staining solution (1:1000 dilution of stock solution in
neutralisation buffer) was distributed across the slides and
incubated at room temperature before scoring (tail length
representing single-strand break density), using a fluor-
escent microscope (Zeiss Axiovert 10, Germany).
Lipid peroxidation
8-Isoprostane and TBARS concentrations were used to
assess lipid peroxidation in the plasma. For TBARS, plasma
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samples and standards (1,1,3,3-tetramethoxypropane)
(100 µl) were mixed with trichloroacetic acid (410mM,
100 µl) and colour reagent (4.6mM thiobarbituric acid,
1.74M glacial acetic acid and 0.67M butylated hydro-
xytoluene, 800 µl) in Eppendorf tubes. After boiling vigor-
ously in water (100 °C) for 1 h, the reaction was stopped by
placing the tubes in an ice bath for 10min. Supernatants
were transferred to a multiwell plate and the absorbance was
measured at 540 nm. The concentration of 8-isoprostane in
plasma samples was determined by competitive enzyme-
linked immunosorbent assay using a commercially available
kit (8-isoprostane EIA Kit 516351, Cayman Chemical, Ann
Arbor, MI), according to the manufacturer’s instructions.
After pretreatment of the plasma sample to concentrate the
total 8-isoprostane content, affinity sorbent (8-isoprostane
affinity sorbent 401113-1, Cayman Chemical, Ann Arbor,
MI) was used.
Protein carbonyls
Protein carbonyl concentration was determined in the
plasma. Anti-DNP (2,4-dinitrophenol) antiserum primary
antibody (1:1000) and peroxidase-labelled secondary
antibody (rat anti-mouse IgE in blocking buffer 1:5000)
were used, following the protocols described by Buss
et al.55 and Alamdari et al.54.
Inflammatory markers
Plasma IL-6, CRP and TNF-α concentrations were
determined using commercially available immunoassay
kits (Human IL-6 Quantikine ELISA Kit (D6050), Human
TNF-alpha Quantikine ELISA Kit (DTA00C) and Human
C-Reactive protein/CRP Quantikine ELISA Kit
(DCRP00)), from R&D Systems (Minnesota, USA).
Concentrations were determined according to the man-
ufacturer’s instructions.
Total antioxidant capacity using the FRAP method
The FRAP method was developed by Benzie and
Strain56. Standards were prepared using a 0–1000 μM
concentration range of ascorbic acid. FRAP reagent—
consisting of acetate buffer (300 mM sodium acetate at
pH 3.6 (3.1 g) into neat 16 mL glacial acid per litre of
buffer solution), TPTZ (2, 4, 6-Tris (2-pyridyl)-S-triazine)
solution (160 mM: 0.05 g/mL–0.1 g TPTZ in 2mL
methanol, then 2mL into 30mL 40mM HCl) and
FeCl3·6H2O solution (0.332 g ferric chloride in 100 mL
ddH2O)—was added to samples/standards on the plate,
incubated for 8 min at room temperature and read at
650 nm. FRAP concentrations were determined by linear
regression relative to ascorbic acid.
Brain-derived neurotrophic factor
Plasma BDNF concentration was determined using a
commercially available immunoassay kit (Human BDNF
ELISA Kit (ab99978), Abcam, Cambridge, UK). Results
using this sandwich ELISA Kit were determined according
to the manufacturer’s instructions.
Psychiatric outcomes
At each assessment time-point, participants completed
the PANSS57, via a structured clinical interview designed
to monitor symptoms of psychosis. The PANSS interview
assesses positive and negative symptoms, and is widely
considered the ‘gold-standard’ method of quantifying
psychotic behaviour. Interviewers were trained in the
completion of PANSS.
Fig. 1 T1 weighted MRI image demonstrating the volume of interest (VOI) pictured. 30 × 30 × 20mm. Placed in the anterior cingulate cortex.
Image above represents axial, frontal and sagittal views from left to right. The metabolite peak on the right shows an example, edited spectra with
labelled glutathione peak at 2.95 mm.
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Data analysis
Data analysis was performed using GraphPad Prism
8 software (version 8.0.1, 2018). At baseline, relationships
between markers were determined using linear regression,
and to assess any difference at baseline between the two
groups, two-sample t tests were used. To assess changes
between different time-points in the study, paired t tests
were used. To compare relationships between marker pre-
intervention/control period vs. mid or post, Pearson’s
correlation coefficient was employed. Biomarkers were
assayed in triplicate, with average values calculated.
Outlying values were identified using the ROUT (Robust
regression and Outlier removal) method (Q= 1%).
Shapiro–Wilk test for normality was used for Gaussian
distribution, with α significance level set at 0.05. Stan-
dardised mean difference (SMD) test was also used to
assess effect size between time points and intervention
groups, using the standard deviation of paired differences.
Results
Baseline
Twenty-two early intervention service users were
recruited and randomised into the study, aged between 17
and 34 (average length of service use, at recruitment, was
19 months). Baseline characteristics are presented below
(Table 1). From a potential caseload of 134, 67 patients
did not meet eligibility criteria. Of the 67 remaining, with
potential for inclusion into the study, 22 were rando-
mised. Reasons for eligible patients not being randomised
included discharge from the early intervention services,
work/university time commitments, no interest in taking
part in the study and an inability to make initial contact
with the patient. Fifteen participants completed the trial,
across the exercise (n= 7) and control (n= 8) groups.
Peripheral biomarker analysis and symptom assessment
was completed for all participants, whereas only four
members of each intervention group were able to com-
plete the MRS brain scan.
Brain and blood GSH
Peripheral whole-blood GSH increased by 6.13% in the
exercise group, but significantly decreased by 24.37% in
the control group (p= 0.04), in a group–time interaction
(SMD= 0.47).
Ineligibility for scanning included foreign metal in the
body (n= 2), anxiety/fear of enclosure in the scanner (n=
6) and injury preventing prolonged periods of time in the
supine position (n= 1). Brain GSH concentration increased
by 8.50%, and 8.80% in the exercise and control groups,
respectively (SMD=−0.06). There was no significant
change in brain GSH data as a result of 12 weeks of exercise
(p= 0.55), but these data are limited by the small sample of
the cohort that were able to be scanned (exercise group
n= 4 and control group n= 4 for pre–post scans).
The Pearson’s correlation coefficient for the relationship
between blood and brain GSH showed that in the control
group, pre and post r values were 0.37 and 0.23, respec-
tively, indicating weak positive correlation at both time
points. The r value for the exercise group pre-intervention
was 0.91, and post intervention 0.06. These changes
indicate that, in this exercising group of participants,
exercise affected peripheral and brain GSH regulation
differently. Both blood and brain GSH changes are pre-
sented in Fig. 2. Additionally, in the exercise group, the
relationship between GSH change and intensity minutes
increase, as a result of being in the intervention, was
strongly positively correlated, for both blood (r= 0.61)
and brain (r= 0.68) measures.
Markers of oxidative damage
Lipid peroxidation (assessed by TBARS (SMD=−0.67)
and isoprostane concentration (SMD= 0.41)), protein
oxidation (assessed by protein carbonylation (SMD=
0.31)) and DNA oxidation (assessed by strand breaks
Table 1 Summary of baseline characteristics, for both
exercise and control groups.
Exercise Control
Average SD Average SD P values
Weight (kg) 82.51 14.69 84.10 16.76 0.82
BMI (kg/m2) 25.45 3.71 25.49 4.65 0.98
Age (years) 23.45 3.75 26.10 5.74 0.22
Duration of illness
(months)
20.56 9.99 18.00 11.70 0.61
Tobacco consumption 73% 64% NA
Cannabis consumption 50% 91% NA
Brain GSH (mM/kg)
(tNAA)
0.254 0.061 0.275 0.044 0.75
Blood GSH (μM) 0.72 0.23 0.77 0.22 0.62
Comet (%) 3.20 1.52 2.54 1.41 0.31
TBARS (μM) 12.82 2.94 12.31 3.34 0.72
Protein carbonyl
(nmol/mg protein)
138.44 42.69 150.52 136.05 0.79
IL-6 (pg/mL) 1.88 0.49 1.6 1.2 0.34
TNF-α (pg/mL) 83.69 13.99 87.25 12.14 0.54
CRP (ng/mL) 2.51 1.37 2.79 1.43 0.65
FRAP (μM) 294.64 57.01 270 36.68 0.26
BDNF (ng/mL) 52.53 20.91 40.56 26.87 0.64
BDNF brain-derived neurotrophic factor, BMI body mass index, CRP C-reactive
protein, FRAP ferric-reducing ability of plasma, GSH glutathione, IL-6 interleukin-
6, TBARS thiobarbituric acid-reactive substances, TNF-α tumour necrosis factor-
alpha.
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(SMD= 0.18)) are presented in Fig. 2. Exercise did not
cause any significant changes in markers of oxidative
stress. Repeated-measures analysis of variance (ANOVA)
showed no difference between time points for each mar-
ker of oxidative damage. Due to the small sample size
represented in this study, median values were used to
better describe the central tendency of the data, since each
measure had a wide range58.
Inflammatory markers
The markers of inflammation CRP, IL-6 and TNF-α
each changed differently in response to the exercise
intervention. IL-6 concentration decreased between pre
and post time-points in both groups: 25.98% in the
exercise group and 43.30% in the control group (SMD=
0.25). CRP decreased by 10.29% in the exercise group and
increased by 12.05% in the control group (SMD=−0.37).
TNF-α decreased in both groups: 4.28% and 6.80% for the
exercise and control groups, respectively (SMD= 0.13).
Repeated-measured ANOVA showed no difference
between time points for each inflammatory marker.
BDNF concentration
Plasma BDNF content increased by 10.38% in the
exercise group (p= 0.70), and declined by 17.52% in the
non-exercising controls (p= 0.64). Despite the negligible
increase in BDNF content in the exercise group over the
full 12 weeks of the intervention period, between mid and
post time-points in the exercise group, plasma BDNF
concentration increased by a much greater margin of
41.58% (p= 0.12, SMD= 0.23).
Cannabis and tobacco consumption
Subgroup analysis was undertaken in the exercise
intervention group in participants who self-identified as
regular cannabis smokers (n= 4), compared with non-
smokers (n= 3). TBARS concentration decreased 1.30%
in non-smokers, but increased 37.76% in smokers, and
isoprostane concentration increased 5.22% in non-
smokers compared to 17.72% in smokers. Protein carbo-
nylation decreased 31.9% in non-smokers and decreased
5.84% in smokers. These effects may have been fortified
by tobacco consumption, since all cannabis smokers were
also tobacco smokers, and only one non-smoker con-
sumed tobacco only. In an analysis of baseline values for
tobacco smokers vs. non-smokers, there was no difference
in any of the biomarkers assessed.
Intensity minutes and markers of inflammation
The potential effect of quantity of exercise (intensity
minutes) on markers of inflammation was assessed
(Fig. 3). ‘Intensity minutes’, measured by the Garmin
Fig. 2 Changes in indices of antioxidant capacity and oxidative stress. a A comparison of whole-blood GSH concentration (μM) (left) vs. cerebral
GSH concentration (mM/kg) (right), pre-intervention vs. post intervention. b Plasma thiobarbituric acid-reactive substances concentration (μM), a
measure of lipid peroxidation. c Plasma 8-isoprostane concentration (pg/mL), a measure of lipid peroxidation. d Single-strand DNA damage from
whole blood (%). e Plasma protein carbonyl concentration (nmol/mg protein). Both GSH measures are expressed as mean and standard deviation. All
oxidative damage markers are expressed as median and interquartile range. * indicates a significant difference between pre- and post measures.
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devices, are representative of the number of minutes of
moderate-intensity physical activity that contribute to
continuous bouts of activity lasting 10min or more. CRP,
IL-6 and TNF-α concentrations at pre-intervention, mid-
point and post intervention were compared with intensity
minutes per day. It can be seen in Fig. 3 that as intensity
minutes increased from baseline to mid-intervention,
resting IL-6 concentration also increased. Levels then fell
as activity levels decreased post intervention. TNF-α
plasma concentration decreased in response to increased
activity, and increased once again post intervention. CRP
decreased throughout the intervention period and was
still decreased post intervention.
Retention, exercise quality and psychopathology
Overall retention to the intervention was 68%, with
attrition rates of 18% and 45% for the exercise and control
groups, respectively. Four members of the exercise group
dropped out, one immediately after baseline assessment,
two during the first week of exercise and one after
10 weeks of intervention duration. Three members of the
control group dropped out just before the 13-week post
assessment was due. Attendance to the exercise sessions
was 83% for the target two training sessions per week, and
41% for three sessions per week. The average duration of
each exercise session was 37.74 min, and the mean
number of sessions attended per week was 2.31, above the
minimum target for the intervention. Exercise session
data are summarised in Table 2. In the assessment of
habitual activity at baseline, mid-intervention and post
intervention, the exercise group demonstrated an increase
from 30.7 min of activity per day to 51.3 during the
intervention. This fell significantly to 21.6 min/day in the
week following the intervention (p= 0.05). The control
groups were similarly active at baseline, with an average of
25.6 min/day, which fell to 7.2 min/day.
There were strong negative correlations between
exercise intervention adherence and TBARS (r=−0.75,
p= 0.08) and protein carbonyl concentration (r=−0.73,
p= 0.09). The PANSS interview assessed symptomology
across positive, negative and general psychopathology
domains. In each of the three domains, exercise either
conferred protection against declining scores observed in
the control group or resulted in a much greater change
between baseline and post-intervention measurement.
There was a 1.44% increase in negative score in partici-
pants in the exercise group, and a 13.89% increase in
participants in the control group (SMD=−0.33). There
was a 17.31% decrease in positive symptoms of PANSS
in participants in the exercise group, and a 7.83%
Fig. 3 Garmin device measured ‘intensity minutes’, alongside markers of chronic inflammation CRP, IL-6 and TNF-α. The grey points
represent ‘intensity minutes’, as derived from the Garmin devices, and the black points respective inflammatory cytokine concnetrations at pre-, mid-
and post-intervention time-points.
Table 2 Summary of bout distribution and HR data for each separate activity type.
Exercise bout modality
Swim Run Cycle Tennis Football Squash Badminton Circuits
% Total sessions 18.3 15.3 3.5 14.9 16.8 4.5 5.9 20.8
Average HR (BPM) 117.5 136.3 137 125.5 139.4 124.5 124.1 121.3
95% CI 111.2–123.8) (130.2–142.4) 117.5–156.5) 118.2–132.8) (132–146.7) (119.2–129.8) (119.8–128.4) (118.7–123.8)
HR heart rate, BPM beats per minute, CI confidence interval.
Fisher et al. Translational Psychiatry          (2020) 10:254 Page 7 of 11
decrease in the non-exercising controls (SMD=−0.18).
Participants in the exercise group reported a 10.98%
decrease in PANSS general score, compared to a 2.82%
decrease observed in participants in the control group
(SMD=−0.24). These data have been assessed alongside
other functional measures that better shape the psychotic
state, and the effects of the exercise intervention in
Fisher et al.45.
Discussion
This exploratory study demonstrated that 12 weeks of
regular exercise training may be sufficient to elicit positive
changes in biomarkers of redox status and inflammation
in a cohort of young men with FEP. The study highlighted
potential differences in the response of GSH to training in
blood and brain. Although some results were not sig-
nificant when analysing individual outcomes (due to small
participant numbers), when taken together, the battery of
outcomes suggest a shift in redox and inflammatory sta-
tus. In many cases, exercise appeared to be protective of
the negative changes that were observed in the control
group, which are likely a result of disease status: either
redox-linked disease progression, treatment or the impact
the disease has on lifestyle factors. These are all repre-
sentative indicators of poorer long-term outcomes for
the patient.
Brain GSH vs. peripheral GSH
The data presented suggest that blood and brain GSH
responded differently to exercise. Exercise caused increased
blood GSH, which is a common response32; however, no
detectable change was seen in brain GSH in this study.
There was no correlation between changes in blood and
brain GSH, for either study group. It should be noted that
the number of participants able to be scanned was less than
those that were able to give a blood sample, and as such
assessment of brain GSH was only possible in a subset of
an already small sample of FEP patients. However, Rai
et al.59 also reported differences in blood and brain GSH
response to exercise. The BBB is impermeable to peripheral
GSH and as such it is probable that the two pools of GSH
are regulated separately, protecting the brain from per-
ipheral chemical changes that could produce toxic effects
to brain function and integrity60. The present study is the
first to assess brain and blood GSH in response to exercise
in a psychosis population.
In addition to the discordant regulation of GSH in brain
and blood, there are a number of methodological con-
siderations that are worthy of note. GSH determination by
MRS does not discriminate between glial, neuronal or
extracellular sources of GSH61, and since GSH con-
centration in astrocytes is 10 times that of neurons, dif-
ferential neuronal regulation may be masked. The
complexity of FEP, as with most mental illnesses, means
that brain GSH has not been identified as having a causal
role in disease pathogenesis, but rather perturbed GSH
metabolism26 alongside other stress-related markers and
antioxidants are believed to create the FEP phenotype. In
the present study, there was most variation in brain GSH
in the exercise group, and given that exercise training can
cause changes in GSH, it may be appropriate to suggest
that exercise may have indeed perturbed brain GSH, but
participant number and confounding factors such as diet,
smoking status and medication made it impossible to
draw any conclusions from these data. From an explora-
tory standpoint, the data presented around GSH regula-
tion warrants further investigation, given its critical role
in health.
Inflammation and redox status
No exercise intervention studies have yet assessed the
effects of training on markers of inflammation in an FEP
population. Exercise resulted in a positive change in many
of the markers of redox status and inflammation. For
example, CRP concentration reduced throughout the
study in response to exercise (−10.29%) compared to an
increase (12.05%) in the control group. This response is
highlighted in Fig. 3, where exercise intensity minutes
increased across the study, and CRP concentration fell. In
a schizophrenia population, a 10-week intervention of
high-intensity exercise resulted in a 66% decrease in
plasma CRP62, matching the results shown in the present
study. Other studies that have assessed CRP in psychotic
disorders reported no change after exercise training63,64.
IL-6 has been described as a myokine, which can act as a
regulator of exercise-induced metabolic changes. IL-6
release is elevated during dynamic exercise65 and thus
explains the observed increased plasma IL-6 concentra-
tion observed at mid-point during this intervention. A
review paper by Gómez-Rubio et al.66 summarised that in
schizophrenia, regular exercise leads to a reduction in
disease-associated IL-6 elevation, as was observed at the
post-intervention measure in the present study.
Exercise training conferred a protective effect for a
number of blood biomarkers, including GSH, BDNF and
TBARS. All of these measures demonstrated greater det-
rimental change in the control group, which may be
associated with disease progression67–69. Increased TBARS,
as a measure of lipid peroxidation, is thought to predate
presentation of psychotic symptoms, in a comparison of
unmedicated FEP patients, chronic schizophrenia patients
and healthy controls17. In that study, the concentration of
TBARS was greater in both patient groups, and greatest in
the chronic schizophrenic population. This is in line with
the results of the present study, which suggest that there is
a disease course-dependent increase in lipid markers of
free-radical-mediated damage, over time. BDNF, a reg-
ulator of neuronal health and synaptic plasticity, can be
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depleted in FEP, via an inflammatory-mediated pathway70.
Increased circulating proinflammatory cytokine con-
centration, demonstrated in this clinical group, down-
regulates BDNF expression71. The current study observed a
variety of responses to exercise in different inflammatory
markers, which partially act to influence BDNF expression
downstream. Most importantly, the protective effect of
exercise was demonstrated as preventing the BDNF
decline observed in the control group. BDNF concentra-
tion increased between the mid-intervention and post-
intervention time-points, with a 22.03% decrease between
baseline and mid-intervention, suggesting a lag-period
between exercise initiation and the beginning of an adap-
tive response to training in this marker. Peripheral BDNF
measures are used as a proxy for brain BDNF, since it is
able to cross the highly restrictive BBB. Measurement in
the plasma is representative of free BDNF that crosses the
BBB, and a strong reflection of the influence of an inter-
vention in the brain, rather than a serum measure that
takes into account platelet secreted BDNF upon activa-
tion72. This study brings together many of the linked
biochemical perturbations observed in FEP, and highlights
the potential of exercise training to normalise indices of
antioxidant depletion, oxidative damage, inflammation and
neuronal function.
Cannabis and tobacco interaction with redox markers
Regular use of cannabis in mental illness is far greater
than the general population (6.6%)73, particularly in psy-
chosis populations (23%)74. When data were assessed by
subgroup in the current study, the positive effects of
exercise that were seen in non-smokers were not observed
in the subgroup of smokers. In a study assessing the redox
effects of regular cannabis consumption in healthy young
people, there was no difference in markers of lipid per-
oxidation or protein carbonylation between smokers and
non-smokers75. However, there are many studies that
show the negative effects of smoking on markers of redox
status76. It is possible that changes in redox status as a
result of cannabis smoking, followed by increases in
markers of oxidative damage do contribute to the
pathology of psychotic disease; however, more investiga-
tion of the specific effects of cannabis use on redox status
in FEP is needed to draw any conclusions. Exercise did
not confer complete protection for markers of free-radical
medicated damage in the current FEP group. In addition,
regular tobacco consumption was prevalent among the
participants of this study (70% smokers, 30% non-smo-
kers). Although the groups were too small to allow further
analysis of the effects of tobacco smoking on adaptation to
exercise, the protective effect of regular training on indi-
ces of oxidative stress in smokers has been highlighted.
One 12-week intervention demonstrated significant
improvements in total antioxidant capacity, GSH
peroxidase and GSH reductase enzymes, alongside a
reduction in lipid peroxidation products in smokers only,
with no adaptive change in a non-smoking control
group77. Although baseline oxidative stress is normally
higher in smokers78,79, the benefits of an exercise inter-
vention
are particularly salient in this FEP population, given the
high percentage of the population who habitually smoke
tobacco.
The impact of exercise on symptoms of psychosis
The changes in biomarker described herein were
accompanied by a positive change in symptom profile as a
result of exercise. The observed changes in symptoms of
FEP indicate that the current intervention design was suf-
ficient to elicit beneficial changes in functional status
(PANSS symptomology), in addition to changes in bio-
markers of redox status and inflammation as a result of
exercise training. This is in concordance with the current
literature; exercise has been shown to be superior to control
conditions in improving indices of symptomology, quality of
life and depressive symptoms27. Additionally, another meta-
analysis showed the value of 90min of moderate-intensity
exercise per week (below the World Health Organisation
recommendation of 150min moderate–vigorous-intensity
exercise per week) in improving psychiatric symptoms80.
Limitations
The principle limitation in this study was a small sample
size, rendering many of our time-point and inter-marker
comparisons statistically insignificant. However, the cur-
rent study did observe a measurable change in redox
status and clinical outcome measures. Not all participants
were able to be assessed for brain GSH do to ineligibility
or inability to enter the brain scanner. The main barrier to
scanning was anxiety of participants to be scanned, but
there were some incidences of metal compounds in the
body, or injury preventing prolonged time in the supine
position. Lastly, despite the opportunity to undertake a
variety of indoor-based activities, poor and unpredictable
weather in the United Kingdom was a factor in partici-
pants’ willingness to engaging in the intervention. This
effect was particularly salient during the winter months.
Confounding factors such as adherence to the interven-
tion, body mass index and cannabis consumption may
have affected the outcomes of this exercise intervention,
together with potential contributions from antipsychotic
medication and duration of illness.
Conclusion
This study, in male patients with FEP, highlighted
the beneficial effects of exercise training on markers of
redox homeostasis. The study showed that 12 weeks of
moderate-intensity exercise training was sufficient to
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reduce markers of lipid oxidation and increase antioxidant
status. In many of the markers assessed in this study,
exercise was able to arrest the changes that were seen in
the control group, which would usually be associated with
FEP. Future studies should use these data to explore more
definitive outcomes, given the feasibility of such an
intervention, and the observed change in markers that
describe several aspects of disease pathology.
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